Anteo Technologies is transforming the way scientists work by providing powerful new tools developed with their patented Mix&Go Activation Reagent. These new tools significantly advance traditional coupling methods, helping to improve medical devices and in-vitro diagnostics, leading to faster detection of disease.
Increasingly complex multifactorial diagnosis of cancer and autoimmune diseases are stretching ELISA beyond its limits. It is restricted to measure only a single protein at a time in a given sample aliquot. Multiplex assays, on the other hand, are highly efficient tools for measuring the levels of multiple proteins in a single sample, thus offering superior evaluation of these complex diseases.
During market research, Anteo identified the most common problems scientists experience transferring from ELISA to Multiplex Assays: Binding difficult antibodies and antigens to microspheres, complex protocols for inexperienced xMAP users, lengthy microsphere and protein preparation before coupling, lack of reproducibility between experiments and limited storage of ready-to-couple microspheres.
From these findings, we developed Anteo Mix&Go (AMG) Activation Kit for Multiplex Microspheres, designed to solve the problems mentioned above.
Using the AMG Activation Kit, scientists are enabled to test even the most problematic proteins on xMap. Activation and coupling takes fewer steps improving efficiency in terms of time and cost to companies globally. Additionally, the ability to store the activated microspheres for use at a later time; up to 1 year, is something that is not possible with EDC coupling chemistry. Another advantage to using the AMG Activation kit is increased stability and functionality of antibodies.
Dr. Joe Maeji, Chief Scientific Officer, Anteo Technologies said, “Combining the benefits of the Multiplex high throughput assay platform together with the rapid and effective binding kinetics of Mix&Go, enables scientists faster detection of multifactorial diseases we currently face today.”
The Data: Four Cytokine Sandwich Assays Developed For ELISA on xMAP
Using the AMG Activation Kit, Anteo have easily transferred four individual cytokine sandwich assays, developed for ELISA, directly onto the xMAP platform in the form of a multiplex assay. This has been done without the need to select different antibody pairs compatible with bead-based assays and without extensive assay optimization. The AMG Kit allows users to benefit from the handling characteristics of passive binding (generally used for ELISA), and from the strength of covalent binding typically used with microspheres.
The results above show high precision and accuracy when solving controls using the standard curve. In this example, the expected versus obtained slope was almost a perfect correlation, with an R2 value > 0.99 and a slope close to 1. This data demonstrates that the AMG Activation Kit for Multiplex Microspheres can be used to effortlessly transfer potentially difficult antibodies and antigens for ELISA methods onto the Luminex multiplex platform, without the need for extensive optimization.